{"id":44585,"date":"2022-06-01T19:01:28","date_gmt":"2022-06-01T17:01:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/"},"modified":"2022-06-01T19:01:28","modified_gmt":"2022-06-01T17:01:28","slug":"worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/","title":{"rendered":"Worldwide Acquired Hemophilia Drugs Industry to 2027 &#8211; by Type, Treatment, Therapy, Distribution Channel and Region &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5559543\/acquired-hemophilia-drugs-market-2021-2027?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=dlqdxj&amp;utm_campaign=1708264+-+Worldwide+Acquired+Hemophilia+Drugs+Industry+to+2027+-+by+Type%2C+Treatment%2C+Therapy%2C+Distribution+Channel+and+Region&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Acquired Hemophilia Drugs Market 2021-2027&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220601006084\/en\/1473516\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220601006084\/en\/1473516\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe global acquired hemophilia drugs market is anticipated to grow at a considerable CAGR during the forecast period.\n<\/p>\n<p>\nThe major factors driving the growth of the market include the rising burden of rare disorder among population globally, increasing awareness of hemophilia, and government contribution towards prevention and control of such disease. Moreover, significant investment by key pharmaceutical companies in R&amp;D of novel therapies for hemophilia is also propelling the expansion of market growth.\n<\/p>\n<p>\nThe global acquired hemophilia drugs market is segmented based on type, treatment, therapy, and distribution channel. Based on type, the market is sub-segmented into hemophilia A, hemophilia B, and hemophilia C. On the basis of treatment, the market is sub-segmented into on-demand and prophylaxis. Based on therapy, the market is sub-categorized into replacement therapy, ITI therapy, and gene therapy. On the basis of distribution channel, the market is sub-segmented into hospital pharmacy, online pharmacy, and retail pharmacy.\n<\/p>\n<p>\nGeographically, the global acquired hemophilia drugs market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World.\n<\/p>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nAptevo Therapeutics\n<\/li>\n<li>\nBayer AG\n<\/li>\n<li>\nCSL Behring\n<\/li>\n<li>\nGenzyme Corp.\n<\/li>\n<li>\nGrifols SA\n<\/li>\n<li>\nF. Hoffman La Roche Ltd.\n<\/li>\n<li>\nOctapharma AG\n<\/li>\n<li>\nPfizer Inc\n<\/li>\n<li>\nSpark Therapeutics, Inc.\n<\/li>\n<li>\nTakeda Pharmaceutical Co. Ltd.\n<\/li>\n<\/ul>\n<p>\n<strong>The Report Covers<\/strong>\n<\/p>\n<ul>\n<li>\nComprehensive research methodology of the global acquired hemophilia drugs market.\n<\/li>\n<li>\nThis report also includes a detailed and extensive market overview with key analyst insights.\n<\/li>\n<li>\nAn exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.\n<\/li>\n<li>\nAnalysis of regional regulations and other government policies impacting the global acquired hemophilia drugs market.\n<\/li>\n<li>\nInsights about market determinants that are stimulating the global acquired hemophilia Drugs market.\n<\/li>\n<li>\nDetailed and extensive market segments with the regional distribution of forecasted revenues.\n<\/li>\n<li>\nExtensive profiles and recent developments of market players.\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Report Summary<\/strong>\n<\/p>\n<p>\n<strong>2. Market Overview and Insights<\/strong>\n<\/p>\n<p>\n2.1. Scope of the Report\n<\/p>\n<p>\n2.2. Analyst Insight &amp; Current Market Trends\n<\/p>\n<p>\n2.2.1. Key Findings\n<\/p>\n<p>\n2.2.2. Recommendations\n<\/p>\n<p>\n2.2.3. Conclusion\n<\/p>\n<p>\n<strong>3. Market Determinants<\/strong>\n<\/p>\n<p>\n3.1. Motivators\n<\/p>\n<p>\n3.2. Restraints\n<\/p>\n<p>\n3.3. Opportunities\n<\/p>\n<p>\n<strong>4. Market Segmentation<\/strong>\n<\/p>\n<p>\n4.1. Global Acquired Hemophilia Drugs Market by Type\n<\/p>\n<p>\n4.1.1. Hemophilia A\n<\/p>\n<p>\n4.1.2. Hemophilia B\n<\/p>\n<p>\n4.1.3. Hemophilia C\n<\/p>\n<p>\n4.2. Global Acquired Hemophilia Drugs Market by Treatment\n<\/p>\n<p>\n4.2.1. On-Demand\n<\/p>\n<p>\n4.2.2. Prophylaxis\n<\/p>\n<p>\n4.3. Global Acquired Hemophilia Drugs Market by Therapy\n<\/p>\n<p>\n4.3.1. Replacement Therapy\n<\/p>\n<p>\n4.3.2. ITI Therapy\n<\/p>\n<p>\n4.3.3. Gene Therapy\n<\/p>\n<p>\n4.4. Global Acquired Hemophilia Drugs Market by Distribution Channel\n<\/p>\n<p>\n4.4.1. Hospital Pharmacy\n<\/p>\n<p>\n4.4.2. Online Pharmacy\n<\/p>\n<p>\n4.4.3. Retail Pharmacy\n<\/p>\n<p>\n<strong>5. Regional Analysis<\/strong>\n<\/p>\n<p>\n5.1. North America\n<\/p>\n<p>\n5.1.1. United States\n<\/p>\n<p>\n5.1.2. Canada\n<\/p>\n<p>\n5.2. Europe\n<\/p>\n<p>\n5.2.1. UK\n<\/p>\n<p>\n5.2.2. Germany\n<\/p>\n<p>\n5.2.3. Italy\n<\/p>\n<p>\n5.2.4. Spain\n<\/p>\n<p>\n5.2.5. France\n<\/p>\n<p>\n5.2.6. Rest of Europe\n<\/p>\n<p>\n5.3. Asia-Pacific\n<\/p>\n<p>\n5.3.1. China\n<\/p>\n<p>\n5.3.2. India\n<\/p>\n<p>\n5.3.3. Japan\n<\/p>\n<p>\n5.3.4. Rest of Asia-Pacific\n<\/p>\n<p>\n5.4. Rest of the World\n<\/p>\n<p>\n<strong>6. Company Profiles<\/strong>\n<\/p>\n<p>\n6.1. Aptevo Therapeutics\n<\/p>\n<p>\n6.2. Bayer AG\n<\/p>\n<p>\n6.3. CSL Behring\n<\/p>\n<p>\n6.4. Genzyme Corp.\n<\/p>\n<p>\n6.5. Grifols SA\n<\/p>\n<p>\n6.6. F. Hoffman La Roche Ltd.\n<\/p>\n<p>\n6.7. Octapharma AG\n<\/p>\n<p>\n6.8. Pfizer Inc\n<\/p>\n<p>\n6.9. Spark Therapeutics, Inc\n<\/p>\n<p>\n6.10. Takeda Pharmaceutical Co. Ltd.\n<\/p>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5559543\/acquired-hemophilia-drugs-market-2021-2027?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=dlqdxj&amp;utm_campaign=1708264+-+Worldwide+Acquired+Hemophilia+Drugs+Industry+to+2027+-+by+Type%2C+Treatment%2C+Therapy%2C+Distribution+Channel+and+Region&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/bnrphp<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;&#116;&#x6f;&#x3a;&#112;&#x72;&#x65;&#115;&#x73;&#x40;r&#x65;&#x73;e&#x61;&#114;c&#x68;&#97;n&#x64;&#109;a&#x72;&#107;e&#x74;&#115;&#46;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">pr&#101;&#115;&#115;&#x40;&#x72;&#x65;&#x73;&#x65;ar&#99;&#104;&#97;&#x6e;&#x64;&#x6d;&#x61;&#x72;ke&#116;&#115;&#46;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Acquired Hemophilia Drugs Market 2021-2027&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global acquired hemophilia drugs market is anticipated to grow at a considerable CAGR during the forecast period. The major factors driving the growth of the market include the rising burden of rare disorder among population globally, increasing awareness of hemophilia, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44585","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Worldwide Acquired Hemophilia Drugs Industry to 2027 - by Type, Treatment, Therapy, Distribution Channel and Region - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Worldwide Acquired Hemophilia Drugs Industry to 2027 - by Type, Treatment, Therapy, Distribution Channel and Region - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Acquired Hemophilia Drugs Market 2021-2027&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global acquired hemophilia drugs market is anticipated to grow at a considerable CAGR during the forecast period. The major factors driving the growth of the market include the rising burden of rare disorder among population globally, increasing awareness of hemophilia, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-01T17:01:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220601006084\/en\/1473516\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Worldwide Acquired Hemophilia Drugs Industry to 2027 &#8211; by Type, Treatment, Therapy, Distribution Channel and Region &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-06-01T17:01:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/\"},\"wordCount\":537,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220601006084\\\/en\\\/1473516\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/\",\"name\":\"Worldwide Acquired Hemophilia Drugs Industry to 2027 - by Type, Treatment, Therapy, Distribution Channel and Region - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220601006084\\\/en\\\/1473516\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-06-01T17:01:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220601006084\\\/en\\\/1473516\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220601006084\\\/en\\\/1473516\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Worldwide Acquired Hemophilia Drugs Industry to 2027 &#8211; by Type, Treatment, Therapy, Distribution Channel and Region &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Worldwide Acquired Hemophilia Drugs Industry to 2027 - by Type, Treatment, Therapy, Distribution Channel and Region - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Worldwide Acquired Hemophilia Drugs Industry to 2027 - by Type, Treatment, Therapy, Distribution Channel and Region - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Acquired Hemophilia Drugs Market 2021-2027&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. The global acquired hemophilia drugs market is anticipated to grow at a considerable CAGR during the forecast period. The major factors driving the growth of the market include the rising burden of rare disorder among population globally, increasing awareness of hemophilia, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-01T17:01:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220601006084\/en\/1473516\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Worldwide Acquired Hemophilia Drugs Industry to 2027 &#8211; by Type, Treatment, Therapy, Distribution Channel and Region &#8211; ResearchAndMarkets.com","datePublished":"2022-06-01T17:01:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/"},"wordCount":537,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220601006084\/en\/1473516\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/","name":"Worldwide Acquired Hemophilia Drugs Industry to 2027 - by Type, Treatment, Therapy, Distribution Channel and Region - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220601006084\/en\/1473516\/21\/logo.jpg","datePublished":"2022-06-01T17:01:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220601006084\/en\/1473516\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220601006084\/en\/1473516\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/worldwide-acquired-hemophilia-drugs-industry-to-2027-by-type-treatment-therapy-distribution-channel-and-region-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Worldwide Acquired Hemophilia Drugs Industry to 2027 &#8211; by Type, Treatment, Therapy, Distribution Channel and Region &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44585"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44585\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}